QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platform Lilly to make a strategic investment in QurCan TORONTO — QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an…
MoH says substandard and falsified medicines remain a global public health threat requiring vigilance and coordinated action The post Fake medicine alert: Why you should buy drugs from licensed…
As the FDA ramps up its effort to accelerate the development of psychedelic therapies, mental health experts on Monday urged the agency to consider certain safety precautions.
[Ghanaian Times] A traditional medical practitioner, Dr Christiana Torvor, has called for intensified public education on cannabis and industrial hemp to address misconceptions and stigma surrounding…
